Cytomx Therapeutics (CTMX) Stock
Clinical stage biotech developing targeted cancer antibody treatments. Here's the price, business snapshot, and what's worth knowing about Cytomx Therapeutics in May 2026.
CytomX Therapeutics (CTMX) is a clinical‑stage biotechnology company developing conditionally activated antibody therapeutics using its Probody platform. The approach is designed to keep antibody drugs inactive in circulation and activate them within the tumour microenvironment, with the goal of widening the therapeutic window and lowering off‑tumour toxicity. Investors should be aware this is an early‑stage company: value is driven by clinical readouts, regulatory progress and potential partnerships or licensing deals rather than steady revenues. As a small‑cap stock, CytomX can be more volatile and may require additional financing to advance programmes. Key considerations for investors include trial results, cash runway, management execution and the broader oncology funding environment. This summary is for educational purposes only and not personalised investment advice; any investment could lose value and past performance is not a reliable indicator of future results.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying CytomX Therapeutics' stock with a target price of $7.07, indicating growth potential.
Financial Health
CytomX Therapeutics is maintaining steady revenue and cash flow, but faces challenges in profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CTMX
FDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketCancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: October 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Probody Activation Platform
Aims to activate antibodies at the tumour site to reduce off‑tumour effects; scientific promise carries clinical and regulatory risk, so outcomes can vary.
Event‑Driven Catalysts
Share moves often follow trial readouts, licensing deals or financing updates; these can create rapid gains or losses depending on outcomes.
Partnering & Licensing
Biotech partnerships can accelerate development and de‑risk programmes, though they depend on negotiation and regulatory progress.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
